Key terms
About YMAB
Y-mAbs Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer. Its services include discovery, protein engineering, clinical and regulatory. Y-mAbs Therapeutics was founded by Thomas Gad in April 2015 and is headquartered in New York, NY.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest YMAB news
Apr 29
5:23pm ET
Y-mAbs Therapeutics Board Member Dr. Ber Announces Resignation
Mar 14
9:33am ET
Y-Mabs Therapeutics CFO Resigns, Ensures Smooth Transition
Mar 06
6:13am ET
Y-mAbs Therapeutics price target raised to $22 from $21 at H.C. Wainwright
Mar 04
10:50am ET
Biotech Alert: Searches spiking for these stocks today
Mar 04
8:43am ET
Y-mAbs Therapeutics price target raised to $26 from $16 at BMO Capital
Mar 04
7:36am ET
Y-mAbs Therapeutics appoints Tagliaferri to board of directors
Mar 04
7:32am ET
Y-mAbs Therapeutics price target raised to $26 from $22 at Canaccord
Feb 29
4:23pm ET
Y-mAbs Therapeutics sees FY24 revenue $95M-$100M, consensus $96.27M
Feb 29
4:22pm ET
Y-mAbs Therapeutics reports Q4 EPS (2c), consensus (20c)
Feb 20
6:26am ET
Buy Rating Affirmed for Y-Mabs Therapeutics on SADA Technology’s Promising Radiotherapy Advancements
Feb 20
6:16am ET
Y-mAbs Therapeutics price target raised to $21 from $11 at H.C. Wainwright
Jan 31
10:56am ET
Biotech Alert: Searches spiking for these stocks today
Apr 15
8:30am ET
STOCK INVESTIGATION NOTICE: Kaskela Law LLC Announces Investigation of Y-mAbs Therapeutics, Inc. (YMAB) and Encourages Long-Term Investors to Contact the Firm
Apr 02
8:30am ET
SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Y-mAbs Therapeutics, Inc. (YMAB) and Encourages Long-Term Investors to Contact the Firm for Additional Information
YMAB Financials
Key terms
Ad Feedback
YMAB Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
YMAB Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range